How to Stop Meth Addiction: A Step-by-Step Treatment Plan

Methamphetamine addiction is treatable, but unlike opioid or alcohol use disorders, there is no single medication that reliably stops cravings or blocks the drug’s effects. Treatment instead relies on a combination of behavioral therapies, emerging pharmacological options, and sustained lifestyle restructuring, delivered across distinct phases that begin with surviving withdrawal and extend well beyond it. The evidence for several of these approaches has strengthened considerably in recent years, and understanding what each phase involves can make the process feel less opaque.

What Withdrawal Actually Looks Like

The first physical barrier to stopping methamphetamine is withdrawal, and it follows a pattern that research has mapped fairly clearly. Within 24 hours of the last dose, symptoms peak sharply: heavy sleeping, increased appetite, and a cluster of depression-related symptoms including low mood, fatigue, and anxiety. Craving is present but, somewhat counterintuitively, it is not the most severe symptom in those first few days. This acute phase lasts roughly seven to ten days, during which overall severity drops in a fairly linear pattern from that initial peak.¹

After the acute phase, a subacute phase sets in that lasts at least two to three additional weeks. Most withdrawal symptoms stay at low levels during this period, but craving behaves differently. One study found that craving did not decrease significantly until the second week of abstinence, and then continued at a reduced but persistent level through the fifth week.² Depression can also linger: animal research shows that repeated methamphetamine exposure causes long-lasting depression-like behavior, including an inability to experience pleasure, that extends well beyond the drug’s clearance from the body.³

No FDA-approved medication specifically targets methamphetamine withdrawal. Medical supervision during this period focuses on supportive care: managing sleep disruption, monitoring mood, and ensuring someone is safe during the depressive lows. The good news is that most acute symptoms resolve without pharmacological intervention. The bad news is that lingering craving and low mood create a window of vulnerability that demands a plan for what comes next.

Getting Into Treatment and Finding the Right Level of Care

One of the most common failure points happens before treatment even starts. A qualitative study of people who visited emergency departments for methamphetamine-related crises found that hospital staff typically addressed the immediate medical problem and stopped there. Participants described being “dealt with without really being dealt with,” receiving fluids and symptom management but no follow-up conversation about substance use treatment or referral to ongoing care.⁴

If you or someone you know is trying to enter treatment, the standard framework used across most U.S. systems is the ASAM (American Society of Addiction Medicine) criteria, which evaluates six dimensions of a person’s situation to recommend the right level of care, from outpatient counseling through residential treatment to medically managed inpatient programs. In practice, how thorough this assessment is varies enormously. A review of 29 different ASAM-based assessment tools found eight different algorithms for translating patient information into care recommendations, with some tools asking just one or two questions per dimension and others asking over a hundred.⁵ The takeaway: if an initial assessment feels cursory and the recommendation does not feel right, it is reasonable to seek a more thorough evaluation.

Behavioral Therapies Are the Backbone

Because no medication works reliably enough to serve as the primary treatment, behavioral therapies carry most of the weight in methamphetamine recovery. Three approaches have the strongest evidence, and they work differently enough that many treatment programs combine them.

Contingency Management

Contingency management, or CM, is the single approach with the largest treatment effects for methamphetamine use disorder among available psychosocial options.⁶ The concept is straightforward: you receive tangible rewards, often gift cards or vouchers, for submitting drug-free urine samples or attending treatment sessions. It sounds almost too simple, and some clinicians have been skeptical of it for that reason. But the results are hard to argue with. A modeling analysis estimated that a 12-week CM program could prevent roughly 117 deaths per year among treated individuals and produce meaningful gains in quality-adjusted life years at a cost of under $10,000 per person, well below standard cost-effectiveness thresholds. A 24-week program did even better, preventing an estimated 153 deaths.⁷

The U.S. Department of Veterans Affairs has already rolled out CM programs, and several states are following. Access remains uneven, partly because federal regulations until recently capped the value of incentives that could be offered. If CM is available in your area, it is worth prioritizing as part of a treatment plan.

Cognitive Behavioral Therapy

CBT for methamphetamine addiction focuses on identifying the thought patterns and situations that trigger use and building concrete skills to handle them differently. A systematic review found that CBT was associated with reductions in methamphetamine use even over very short courses of just two to four sessions.⁸ A randomized controlled trial testing an eight-session CBT program that covered cognitive restructuring, craving management, and relapse prevention found a roughly 39% reduction in craving intensity and a 27% improvement in stress coping strategies among participants.⁹

The Matrix Model

The Matrix Model is a structured outpatient program specifically developed for stimulant users. It combines relapse prevention groups, educational sessions, social support groups, individual counseling, and regular drug testing over a 16-week period. The approach is directive but nonconfrontational, keeping the focus on current behavior rather than digging into past trauma during early recovery.¹⁰ Research on the model has shown a clear dose-response relationship: people who stayed in treatment longer had better abstinence outcomes at six-month follow-up, and being drug-free during treatment was a strong predictor of staying drug-free afterward.¹¹

Medications Under Investigation

There is no FDA-approved medication for methamphetamine use disorder, but several candidates have shown enough promise that clinicians sometimes use them off-label. The most talked-about is the combination of injectable naltrexone and oral bupropion. A landmark two-stage trial published in the New England Journal of Medicine found that about 14% of participants on the combination had a treatment response, compared with roughly 3% on placebo.¹² A 14% response rate sounds modest, and it is, but it represents a roughly five-fold improvement over placebo and the treatment effect held up for both men and women in secondary analyses.¹³

Mirtazapine, an antidepressant, has also shown a signal across multiple trials. In one early randomized trial, mirtazapine reduced methamphetamine-positive urine results from about 73% of participants at baseline to 44%, compared with a much smaller decline in the placebo group.¹⁴ A larger trial among men who have sex with men and transgender women found that mirtazapine significantly reduced methamphetamine-positive urine results through 36 weeks and improved sleep quality during withdrawal.¹⁵ A more recent and larger trial found that mirtazapine reduced methamphetamine use days by about two days per month more than placebo, though it came with higher rates of drowsiness and weight gain, and nearly a quarter of participants discontinued it due to side effects.¹⁶

Neither of these medications is a cure, and clinicians generally view them as add-ons to behavioral therapy rather than standalone treatments. If your provider suggests trying one, it is worth understanding that the goal is usually to take the edge off enough that you can engage more fully with the behavioral work.

When Mental Health Problems Complicate Recovery

Methamphetamine use frequently triggers or worsens psychiatric symptoms, and disentangling what is caused by the drug from what is an independent mental health condition is one of the harder problems in treatment. Psychosis is the most dramatic example. In a study of psychiatric inpatients with methamphetamine-induced psychosis, the most common symptoms were persecutory delusions, auditory hallucinations, and violence. For about a third of those patients, psychotic symptoms took more than a month to resolve, even with antipsychotic medication.¹⁷

The key clinical question is whether these symptoms reflect a primary psychotic disorder like schizophrenia that methamphetamine unmasked, or a substance-induced psychosis that will resolve with sustained abstinence. Careful assessment of the timing of symptoms relative to drug use, combined with urine testing and input from family or close contacts, helps distinguish the two. Antipsychotic medications and benzodiazepines are commonly used for acute episodes, though symptoms sometimes resolve on their own if the person can stay abstinent long enough.¹⁸

Depression is more universally present. As noted in the withdrawal section, depressive symptoms are a core feature of early abstinence. But for some people, depression precedes methamphetamine use or persists long after the drug has cleared. Integrated treatment that addresses both the addiction and the mood disorder simultaneously generally produces better outcomes than treating them sequentially. If you feel your treatment is only addressing one side of the equation, it is worth raising that directly with your provider.

Your Brain Does Recover, But It Takes Time

One of the most discouraging things people hear about methamphetamine is that it causes lasting brain damage. There is truth to this, but the picture is more nuanced and more hopeful than the scare-tactic version suggests. Methamphetamine does cause long-lasting damage to dopamine nerve endings in the brain’s reward circuitry.¹⁹ But recovery is also real.

An imaging study found that stored dopamine levels, which were depleted in methamphetamine users tested within about three days of their last dose, returned to normal levels in those who maintained abstinence for roughly ten days.²⁰ That is strikingly fast. Longer-term recovery has also been documented: after months of abstinence, brain metabolism in the thalamus recovered significantly, and this recovery was associated with measurable improvements in motor function and verbal memory. Some deficits in the striatum persisted, but the overall trajectory was toward meaningful functional improvement.²¹

Exercise appears to accelerate this process. A review of the evidence found that methamphetamine users who engaged in regular physical activity showed improvements in fitness, emotional well-being, and lower relapse rates compared with those who did not exercise. The underlying mechanisms seem to involve multiple pathways, including brain chemistry, oxidative stress reduction, and even the growth of new brain cells.²² If there is one low-cost, no-side-effect intervention that everyone in recovery should be doing, it is physical activity.

Building a Life That Supports Sobriety

The behavioral therapies described above work in clinical settings, but most of a person’s time is spent outside of clinics. The Community Reinforcement Approach, or CRA, is a treatment model built around this reality. Based on the idea that the environment a person lives in has to compete with drug use, CRA helps people restructure their daily lives so that drug-free activities become genuinely rewarding. This means concrete work on relationships, employment, recreation, and social networks.²³

Research on social determinants of health underscores why this matters. Employment has been linked to better recovery outcomes, including fewer positive drug tests and longer abstinence periods. Conversely, unstable housing was associated with a nearly 50% faster time to relapse among people who inject drugs.²⁴ Criminal justice system involvement also predicted worse outcomes. These findings point to something important: treatment alone, no matter how good, exists within a social context. If someone leaves a residential program and returns to homelessness and unemployment, the odds are stacked against them regardless of the clinical skills they learned.

Practical steps that tend to matter most in the months after initial treatment include securing stable housing before or immediately after discharge, pursuing employment or structured daily activities, and actively building relationships with people who do not use drugs. Twelve-step groups like Crystal Meth Anonymous and secular alternatives like SMART Recovery serve a dual role here: they provide both accountability and a sober social network. None of this is glamorous, but the evidence consistently shows that the social scaffolding around a person’s recovery is at least as important as the clinical intervention itself.

Harm Reduction When Abstinence Is Not Immediate

Not everyone who wants to stop using methamphetamine can do so immediately, and a growing body of evidence supports harm reduction strategies during the transition. One pressing concern is the contamination of methamphetamine supplies with fentanyl. A qualitative study found that methamphetamine users employ strategies like buying from trusted sources and using fentanyl test strips to reduce the risk of accidental opioid exposure.²⁵ Fentanyl test strips, which can detect the presence of fentanyl in a drug sample before use, are being evaluated in randomized trials as a scalable harm reduction tool distributed through naloxone programs in both urban and rural settings.²⁶

Harm reduction is not a competing philosophy to abstinence-oriented treatment. For many people, it is the realistic bridge between active use and full engagement with recovery. Staying alive and avoiding overdose is the prerequisite to everything else.

Emerging Treatments Worth Watching

Several experimental approaches are far enough along to deserve mention, even if they are not yet part of standard care.

Repetitive transcranial magnetic stimulation (rTMS) uses magnetic fields applied to the scalp to stimulate or inhibit specific brain regions. A meta-analysis of double-blind randomized controlled trials found that rTMS significantly reduced craving scores in people with methamphetamine use disorder compared with sham treatment.²⁷ Multiple studies have found that stimulating specific regions of the prefrontal cortex across five to twenty sessions can reduce both cue-induced and unprovoked craving, with effects that persist for some time after the treatment course ends.²⁸ The limitation is access: rTMS requires specialized equipment and trained operators, and it is not yet widely available outside research settings for this indication.

Further out on the research timeline, immunotherapy approaches are being developed that could fundamentally change how methamphetamine addiction is treated. The idea is to create antibodies, either through a vaccine or through direct administration of lab-made antibodies, that bind methamphetamine in the bloodstream and prevent it from reaching the brain. Preclinical work has shown that combining a methamphetamine-conjugate vaccine with monoclonal antibodies produces an anti-methamphetamine immune response that, in rats, significantly reduced methamphetamine concentrations in the brain even four months after treatment.²⁹ This remains preclinical, so it is years away from clinical use, but it represents one of the more creative lines of attack on a notoriously difficult problem.

Another area of growing interest involves the gut microbiome. Methamphetamine exposure disrupts the composition of gut bacteria, depleting beneficial species and promoting inflammatory ones. These microbial changes appear to worsen brain inflammation and neurotransmitter imbalances through the gut-brain axis.³⁰ Animal studies have shown that interventions targeting the gut microbiome, including fecal transplants and antibiotic-induced microbiome changes, can influence methamphetamine-related neurotoxicity and behavioral symptoms.³¹ Whether this translates into useful treatments for humans remains to be seen, but it opens an entirely new avenue of intervention that would not have been taken seriously a decade ago.